Celecoxib for rheumatoid arthritis

Garner, Sarah; Fidan, Dogan; Frankish, Ruth R; Judd, Maria; Shea, Beverley; Towheed, Tanveer; Tugwell, Peter; Wells, George A.

doi:10.1002/14651858.cd003831

Cited by 37 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, joints from RA patients exhibited abundant COX expression, to higher levels than those found in synovial tissues from osteoarthritis patients or nonarthritic synovial tissues [24]. Therefore, COX-2-targeted therapy is under consideration for the treatment of RA by inhibiting inflammation and angiogenesis [25][26][27]. In the present study, it was shown that MDR also inhibited COX-2 mRNA expression in a concentration-dependent fashion.…”

Section: Discussionmentioning

confidence: 52%

Methanol extract of Dioscoreae Rhizoma inhibits pro-inflammatory cytokines and mediators in the synoviocytes of rheumatoid arthritis

Kim

Kang³

et al. 2004

International Immunopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 52%

Methanol extract of Dioscoreae Rhizoma inhibits pro-inflammatory cytokines and mediators in the synoviocytes of rheumatoid arthritis

Kim

Kang³

et al. 2004

International Immunopharmacology

View full text Add to dashboard Cite

“…53,[112][113][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130] Two foreign language systematic reviews were not included due to difficulties in obtaining the references within the project time frame. 131,132 Three aspects of these reviews were assessed in detail:…”

Section: Current Use Of Nsaidsmentioning

confidence: 99%

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Chen

Jobanputra²,

Barton³

et al. 2008

Health Technol Assess

268

174

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: P Jobanputra has received funding from Pfizer for two research studies: 'quality of care in patients with musculoskeletal pain who use NSAIDs' and 'perception of risk in relation to NSAID use for patients with RA and OA'. He has also been entertained, paid to speak and provided with financial assistance for educational purposes by many manufacturers of non-steroidal anti-inflammatory drugs, new and old. RS Taylor has undertaken paid presentations for Pfizer (Canada) and Novartis (UK) not related to rheumatoid arthritis or osteoarthritis management. HTA Published April 2008This report should be referenced as follows:Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in th...

show abstract

“…However, NSAIDs including COX-2 inhibitors for pain relief in OA is accompanied by increased risk of adverse effects in long-term treatment such as gastrointestinal problems and cardiovascular risks [13]. Furthermore, no evidence of any clinically significant drug interactions for glucosamine or chondroitin was reported as well.…”

Section: Safety Profile Of Glucosamine and Chondroitinmentioning

confidence: 99%

“…However, some studies have indicated that NSAIDs are only used to treat symptoms without correction of the degenerative disorder of the connective tissue. Furthermore, the long-term use of NSAIDs causes potential adverse effects on the gastrointestinal and cardiovascular systems, which are mainly popular among elderly patients [13]. Therefore it can be deduced that medical treatments available for OA are moderately effective and are mostly directed at short-term pain relief, In addition, side effects of these treatments can be quite significant.…”

Section: Introductionmentioning

confidence: 99%

Nutraceutical Formulations Containing Glucosamine and Chondroitin Sulphate in the Treatment of Osteoarthritis: Emphasis on Clinical Efficacy and Formulation Challenges

Agiba¹

2017

Int J Curr Pharm Sci

View full text Add to dashboard Cite

Osteoarthritis (OA) is essentially a debilitating disease symptomatized by a gradual loss of articular joint cartilage, causing painful impairment among the population of different ages, particularly patients over the age of 50 y. Nutraceuticals; namely glucosamine and chondroitin have been widely used in the treatment of OA. The chondroprotective properties of the aforementioned agents have been reported, allowing the repair and recovery of the articular surface in OA. The purpose of this review article is to report the current evidence for the use of glucosamine and chondroitin sulphate in the treatment of knee OA with emphasis on their indications for clinical use, effectiveness and safety. It also highlights the role of some advanced formulation technologies in optimizing the delivery of those drugs.

show abstract

Celecoxib for rheumatoid arthritis

Abstract: For an individual with RA the potential benefits of celecoxib need to be balanced against the uncertainty that the short-term reduced incidence of upper GI complications are maintained in the long-term and its increased cost in comparison to traditional NSAIDs.

Cited by 37 publications

References 15 publications

Methanol extract of Dioscoreae Rhizoma inhibits pro-inflammatory cytokines and mediators in the synoviocytes of rheumatoid arthritis

Methanol extract of Dioscoreae Rhizoma inhibits pro-inflammatory cytokines and mediators in the synoviocytes of rheumatoid arthritis

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Nutraceutical Formulations Containing Glucosamine and Chondroitin Sulphate in the Treatment of Osteoarthritis: Emphasis on Clinical Efficacy and Formulation Challenges

Contact Info

Product

Resources

About